Depakene Side Effects

Generic name: valproic acid

Medically reviewed by Drugs.com. Last updated on May 9, 2024.

Note: This document provides detailed information about Depakene Side Effects associated with valproic acid. Some dosage forms listed on this page may not apply specifically to the brand name Depakene.

Applies to valproic acid: oral capsule delayed release, oral capsule liquid filled, oral solution, oral syrup, oral tablet delayed release, oral tablet extended release.

Important warnings This medicine can cause some serious health issues

Oral route (capsule, delayed release)

Hepatotoxicity (some cases fatal), usually occurring during the first 6 months of treatment, has been reported in patients receiving valproate and its derivatives.

Children younger than 2 years and patients with hereditary mitochondrial disease are at a considerably increased risk of developing fatal hepatotoxicity.

Use is contraindicated in patients with known mitochondrial disorders caused by mitochondrial DNA polymerase gamma (POLG) mutations and in children younger than 2 years in which mitochondrial disorder is clinically suspected.

Failure of other anticonvulsants is the only indication for valproate use in patients older than 2 years with hereditary mitochondrial disease.

Perform POLG mutation screening as clinically indicated.

Monitor patients closely and perform liver function tests prior to therapy and at frequent intervals thereafter, especially during the first 6 months.

Valproate can impair cognitive development with prenatal exposure and produce major congenital malformations, particularly neural tube defects (eg, spina bifida), and neurodevelopmental disorders.

Valproate is contraindicated for prophylaxis of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception.

Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable.

In such situations, effective contraception should be used.

Life-threatening pancreatitis has been reported in both children and adults receiving valproate.

Cases have occurred shortly after initiation as well as several years after use.

If pancreatitis is diagnosed, valproate should ordinarily be discontinued.

Oral route (syrup; capsule, liquid filled)

Hepatotoxicity (some cases fatal), usually occurring during the first 6 months of treatment, has been reported in patients receiving valproate and its derivatives.

Children younger than 2 years and patients with hereditary mitochondrial disease are at a considerably increased risk of developing fatal hepatotoxicity.

Use is contraindicated in patients with known mitochondrial disorders caused by mitochondrial DNA polymerase gamma (POLG) mutations and in children younger than 2 years in which mitochondrial disorder is clinically suspected.

Failure of other anticonvulsants is the only indication for valproate use in patients older than 2 years with hereditary mitochondrial disease.

Perform POLG mutation screening as clinically indicated.

Monitor patients closely and perform liver function tests prior to therapy and at frequent intervals thereafter, especially during the first 6 months.

Valproate can impair cognitive development with prenatal exposure and produce major congenital malformations, particularly neural tube defects (eg, spina bifida).

Valproate is contraindicated for prophylaxis of migraine headaches in pregnant women and women of childbearing potential who are not using effective contraception.

Valproate should not be administered to a woman of childbearing potential unless other medications have failed or are otherwise unacceptable.

Effective contraception should be used in such situations.

Life-threatening pancreatitis has been reported in both children and adults receiving valproate.

Cases have occurred shortly after initiation as well as several years after use.

If pancreatitis is diagnosed, valproate should ordinarily be discontinued.

Oral route (tablet, delayed release; capsule, delayed release; tablet, extended release)

Hepatotoxicity (some cases fatal), usually occurring during the first 6 months of treatment, has been reported in patients receiving valproate and its derivatives.

Children younger than 2 years and patients with hereditary mitochondrial disease are at a considerably increased risk of developing fatal hepatotoxicity.

For these patients under 2 years, valproate sodium should be used with extreme caution as a sole agent.

Use is contraindicated in patients with known mitochondrial disorders caused by mitochondrial DNA polymerase gamma (POLG) mutations and in children younger than 2 years in which mitochondrial disorder is clinically suspected.

Failure of other anticonvulsants is the only indication for divalproex sodium in patients older than 2 years with hereditary mitochondrial disease.

Perform POLG mutation screening as clinically indicated.

Monitor patients closely and perform liver function tests prior to therapy and at frequent intervals thereafter, especially during the first 6 months.

Valproate can impair cognitive development with prenatal exposure and produce major congenital malformations, particularly neural tube defects (eg, spina bifida).

Valproate is contraindicated for prophylaxis of migraine headaches in pregnant women and women of childbearing potential who are not using effective contraception.

Valproate should not be administered to a woman of childbearing potential unless other medications have failed or are otherwise unacceptable.

Effective contraception should be used in such situations.

Life-threatening pancreatitis has been reported in both children and adults receiving valproate.

Cases have occurred shortly after initiation as well as several years after use.

If pancreatitis is diagnosed, valproate should ordinarily be discontinued.

Serious side effects of Depakene

Along with its needed effects, valproic acid (the active ingredient contained in Depakene) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking valproic acid:

More common side effects

• black, tarry stools
• bleeding gums
• bloating or swelling of the face, arms, hands, lower legs, or feet
• blood in the urine or stools
• confusion
• cough
• crying
• delusions of persecution, mistrust, suspiciousness, or combativeness
• diarrhea
• difficult or labored breathing
• dysphoria
• false beliefs that cannot be changed by facts
• false or unusual sense of well-being
• feeling of unreality
• fever
• general feeling of discomfort or illness
• headache
• hoarseness
• joint pain
• loss of appetite
• lower back or side pain
• mental depression
• muscle aches and pains
• nausea
• nervousness
• painful or difficult urination
• pinpoint red spots on the skin
• poor insight and judgment
• problems with memory or speech
• quick to react or overreact emotionally
• rapid weight gain
• rapidly changing moods
• runny nose
• sense of detachment from self or body
• shakiness in the legs, arms, hands, or feet
• shivering
• sleepiness or unusual drowsiness
• sore throat
• sweating
• tightness in the chest
• tingling of the hands or feet
• trembling or shaking of the hands or feet
• trouble recognizing objects
• trouble sleeping
• trouble thinking and planning
• trouble walking
• unusual bleeding or bruising
• unusual tiredness or weakness
• unusual weight gain or loss
• vomiting

Less common side effects

• abnormal dreams
• absence of or decrease in body movement
• anxiety
• bloody nose
• bloody or cloudy urine
• blurred vision
• burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
• change in personality
• change in walking and balance
• changes in patterns and rhythms of speech
• chest pain
• clumsiness or unsteadiness
• cold sweats
• constipation
• dark urine
• deep or fast breathing with dizziness
• degenerative disease of the joint
• difficulty with moving
• discouragement
• dizziness
• dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
• dry mouth
• excessive muscle tone
• fast, irregular, pounding, or racing heartbeat or pulse
• fear
• feeling of warmth or heat
• feeling sad or empty
• flushing or redness of the skin, especially on the face and neck
• frequent urge to urinate
• heavy non-menstrual vaginal bleeding
• increased need to urinate
• indigestion
• irritability
• lack of appetite
• lack of coordination
• large, flat, blue or purplish patches in the skin
• leg cramps
• lip smacking or puckering
• loss of bladder control
• loss of interest or pleasure
• loss of strength or energy
• multiple swollen and inflamed skin lesions
• muscle pain or stiffness
• muscle tension or tightness
• normal menstrual bleeding occurring earlier, possibly lasting longer than expected
• numbness of the feet, hands and around mouth
• pains in the stomach, side, or abdomen, possibly radiating to the back
• passing urine more often
• pounding in the ears
• puffing of the cheeks
• rapid or worm-like movements of the tongue
• rapid weight gain
• restlessness
• seeing, hearing, or feeling things that are not there
• shakiness and unsteady walk
• slurred speech
• small red or purple spots on the skin
• sweating
• swollen joints
• tiredness
• trouble with concentrating
• trouble with speaking
• twitching
• uncontrolled chewing movements
• uncontrolled movements of the arms and legs
• unsteadiness, trembling, or other problems with muscle control or coordination
• vomiting of blood or material that looks like coffee grounds
• yellow eyes or skin

Incidence not known

• aggression
• bladder pain
• blistering, peeling, loosening of the skin
• blisters on the skin
• bone pain, tenderness, or aching
• chest discomfort
• cloudy urine
• decrease in height
• decreased urine output
• difficulty swallowing
• feeling that others are watching you or controlling your behavior
• feeling that others can hear your thoughts
• feeling, seeing, or hearing things that are not there
• hives, itching, skin rash
• increased sensitivity of the skin to sunlight
• increased thirst
• irritability
• joint or muscle pain
• loss of balance control
• loss of consciousness
• mask-like face
• pain in the back, ribs, arms, or legs
• pain or swelling in the arms or legs without any injury
• puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
• red skin lesions, often with a purple center
• red, irritated eyes
• redness or other discoloration of the skin
• seizures
• severe mood or mental changes
• severe sunburn
• shuffling walk
• slow heartbeat
• slowed movements
• slurred speech
• sores, ulcers, or white spots in the mouth or on the lips
• stiffness of the arms and legs
• swelling of the face, ankles, or hands
• swollen or painful glands
• tic-like (jerky) movements of the head, face, mouth, and neck
• unusual behavior

Get emergency help immediately if any of the following symptoms of overdose occur while taking valproic acid:

Symptoms of overdose

• change in consciousness
• fainting
• loss of consciousness
• slow or irregular heartbeat

Other side effects of Depakene

Some side effects of valproic acid may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

• belching
• body aches or pain
• change in vision
• congestion
• continuing ringing or buzzing or other unexplained noise in the ears
• hair loss or thinning of the hair
• hearing loss
• heartburn
• impaired vision
• lack or loss of strength
• loss of memory
• problems with memory
• seeing double
• tender, swollen glands in the neck
• uncontrolled eye movements
• voice changes
• weight gain
• weight loss

Less common side effects

• absent, missed, or irregular menstrual periods
• burning, dry, or itching eyes
• change in taste or bad unusual or unpleasant (after) taste
• coin-shaped lesions on the skin
• cough producing mucus
• cramps
• dandruff
• discharge or excessive tearing
• dry skin
• earache
• excess air or gas in the stomach or bowels
• eye pain
• feeling of constant movement of self or surroundings
• full feeling
• heavy bleeding
• increased appetite
• itching of the vagina or genital area
• loss of bowel control
• neck pain
• oily skin
• pain
• pain during sexual intercourse
• pain or tenderness around the eyes and cheekbones
• passing gas
• rash with flat lesions or small raised lesions on the skin
• redness or swelling in the ear
• redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid
• redness, swelling, or soreness of the tongue
• sensation of spinning
• sneezing
• stiff neck
• stopping of menstrual bleeding
• thick, white vaginal discharge with no odor or with a mild odor

Incidence not known

• breast enlargement
• changes in hair color or texture
• discoloration of the fingernails or toenails
• increased hair growth, especially on the face
• unexpected or excess milk flow from the breasts

For healthcare professionals

Applies to valproic acid: injectable solution, intravenous solution, oral capsule, oral delayed release capsule, oral liquid.

General adverse events

The most commonly reported side effects at the start of therapy include nausea, vomiting, and indigestion; these effects are usually transient. Sedative effects occur most often in patients receiving combination therapy.^[Ref]

Psychiatric

• Very common (10% or more): Nervousness
• Common (1% to 10%): Abnormal dreams, agitation, anxiety, aggression, confusion, depression, emotional lability, hallucinations, insomnia, personality disorder, thinking abnormalities
• Rare (less than 0.1%): Abnormal behavior, learning disorder, psychomotor hyperactivity
• Frequency not reported: Behavioral deterioration, hostility, psychosis
• Postmarketing reports: Emotional upset, disturbance in-attention^[Ref]

Respiratory

• Very common (10% or more): Flu syndrome, respiratory infection
• Common (1% to 10%): Bronchitis, dyspnea, epistaxis, increased cough, pharyngitis, pneumonia, rhinitis, sinusitis
• Uncommon (0.1% to 1%): Pleural effusion^[Ref]

Renal

• Rare (less than 0.1%): Reversible Fanconi's syndrome, tubulointerstitial nephritis^[Ref]

Dermatologic

• Very common (10% or more): Alopecia
• Common (1% to 10%): Discoid lupus erythematosus, dry skin, ecchymosis, furunculosis, maculopapular rash, petechia, pruritus, rash, seborrhea
• Uncommon (0.1% to 1%): Abnormal hair texture, abnormal hair growth, hair color changes, sweating
• Rare (0.01% to 0.1%): Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis
• Very rare (less than 0.01%): Acne, hirsutism
• Frequency not reported: Angioedema, generalized pruritus, photosensitivity
• Postmarketing reports: Nail and nail bed disorders^[Ref]

Endocrine

• Uncommon (0.1% to 1%): Hyperandrogenism, syndrome of inappropriate ADH secretion
• Rare (less than 0.1%): Hypothyroidism
• Very rare (less than 0.01%): Gynecomastia
• Frequency not reported: Abnormal thyroid function tests, elevated serum testosterone concentrations, parotid gland swelling, breast enlargement, galactorrhea,^[Ref]

Gastrointestinal

• Very common (10% or more): Abdominal pain, diarrhea, dyspepsia, gingival disorder, nausea, vomiting
• Common (1% to 10%): Constipation, dry mouth, eructation, fecal incontinence, flatulence, gastralgia, gastroenteritis, glossitis, periodontal abscess, hematemesis, stomatitis
• Uncommon (0.1% to 1%): Pancreatitis (life-threatening)^[Ref]

Cardiovascular

• Common (1% to 10%): Edema, hypertension, hypotension, palpitations, postural hypotension, peripheral edema, tachycardia, vasodilation
• Frequency not reported: Bradycardia, cutaneous vasculitis, hematoma formation^[Ref]

Genitourinary

• Common (1% to 10%): Amenorrhea, cystitis, dysmenorrhea, dysuria, enuresis, metrorrhagia, urinary incontinence, urinary frequency, vaginal hemorrhage, vaginitis
• Frequency not reported: Polycystic ovary disease

Post marketing reports: Irregular menses, secondary amenorrhea, azoospermia, aspermia, decreased sperm count, decreased spermatozoa motility, male infertility, and abnormal spermatozoa morphology, urinary tract infection^[Ref]

Hematologic

• Very common (10% or more): Thrombocytopenia
• Common (1% to 10%): Anemia, hemorrhage
• Uncommon (0.1% to 1%): Leucopenia, pancytopenia
• Rare (less than 0.1%): Abnormal coagulation tests (e.g., prolonged prothrombin time, prolonged activated partial thromboplastin time, prolonged thrombin time, prolonged INR), agranulocytosis, bone marrow failure, decreased coagulation factors, including pure red cell aplasia, macrocytosis
• Frequency not reported: Aplastic anemia, bone marrow suppression, bruising, eosinophilia, frank hemorrhage, hypofibrinogenemia, anemia including macrocytic with or without folate deficiency, relative lymphocytosis
• Postmarketing reports: Relative lymphocytosis, macrocytosis, agranulocytosis, acute intermittent porphyria, Fanconi's syndrome^[Ref]

Hepatic

• Common (1% to 10%): Increased liver enzymes (particularly early in treatment), liver injury, SGOT increased, SGPT increased
• Frequency not reported: Severe liver damage (including hepatic failure sometimes resulting in death), increased serum bilirubin, abnormal changes in other liver function tests^[Ref]

Hypersensitivity

• Frequency not reported: Allergic reaction, anaphylaxis, hypersensitivity^[Ref]

Local

• Common (1% to 10%): Injection site pain, injection site reaction
• Uncommon (0.1% to 1%): Injection site inflammation^[Ref]

Metabolic

• Very common (10% or more): Anorexia
• Common (1% to 10%): Weight loss/gain, increased appetite, hyponatremia
• Rare (less than 0.1%): Hyperammonemia
• Frequency not reported: Acute intermittent porphyria, minor elevations of LDH (dose related), decreased carnitine concentrations, hyperglycinemia^[Ref]

Musculoskeletal

• Common (1% to 10%): Arthralgia, arthrosis, leg cramps, myalgia, myasthenia, twitching
• Uncommon (0.1% to 1%): Decreased bone mineral density, osteopenia, osteoporosis and fractures on long term therapy
• Rare (less than 0.1%): Rhabdomyolysis, systemic lupus erythematosus
• Frequency not reported: Bone pain
• Postmarketing reports: Fractures, weakness^[Ref]

Nervous system

• Very common (10% or more): Dizziness, headache, somnolence, tremor
• Common (1% to 10%): Abnormal gait, amnesia, catatonic reaction, convulsion, disturbance in attention, dysarthria, extrapyramidal disorder, hypertonia, hypokinesia, incoordination, increased reflexes, memory impairment, nystagmus, paraesthesia, speech disorder, stupor, tardive dyskinesia, taste perversion
• Uncommon (0.1% to 1%): Ataxia, coma, encephalopathy, lethargy, reversible parkinsonism
• Rare (less than 0.1%): Cognitive disorder, reversible dementia associated with reversible cerebral atrophy
• Frequency not reported: Cerebral atrophy, dementia
• Postmarketing reports: Paradoxical convulsion, parkinsonism^[Ref]

Ocular

• Very common (10% or more): Amblyopia/blurred vision, diplopia
• Common (1% to 10%): Abnormal vision, conjunctivitis, diplopia, dry eyes, eye pain^[Ref]

Oncologic

• Rare (less than 0.1%): Myelodysplastic syndrome^[Ref]

Other

• Very common (10% or more): Asthenia
• Common (1% to 10%): Back pain, chills, deafness, ear disorder, ear pain, face edema, fever, malaise, otitis media, tinnitus, vertigo
• Frequency not reported: Hypothermia, weakness, hearing loss^[Ref]

Further information

Depakene side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer